The benefits and risks of alemtuzumab in multiple sclerosis

被引：0

作者：

Ontaneda, Daniel ^{[1
]}

Cohen, Jeffrey A. ^{[1
]}

机构：

[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Neurol Inst, Cleveland, OH 44106 USA

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2013年 / 9卷 / 03期

关键词：

alemtuzumab; efficacy; multiple sclerosis; risk; THERAPEUTIC LYMPHOCYTE DEPLETION; DISEASE;

D O I：

10.1586/ECI.13.1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：189 / 191

页数：3

共 19 条

[1] Alemtuzumab in the treatment of chronic lymphocytic lymphoma [J].

Boyd, Kevin ;

Dearden, Claire E. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (04) :525-533

[2] Anti-glomerular basement membrane disease after alemtuzumab [J].

Clatworthy, Menna R. ;

Wallin, Elizabeth F. ;

Jayne, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (07) :768-769

[3] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[4] Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial [J].

Coles, A. J. ;

Fox, E. ;

Vladic, A. ;

Gazda, S. K. ;

Brinar, V. ;

Selmaj, K. W. ;

Skoromets, A. ;

Stolyarov, I. ;

Bass, A. ;

Sullivan, H. ;

Margolin, D. H. ;

Lake, S. L. ;

Moran, S. ;

Palmer, J. ;

Smith, M. S. ;

Compston, D. A. S. .

NEUROLOGY, 2012, 78 (14) :1069-1078

[5] The window of therapeutic opportunity in multiple sclerosis [J].

Coles, AJ ;

Cox, A ;

Le Page, E ;

Jones, J ;

Trip, SA ;

Deans, J ;

Seaman, S ;

Miller, DH ;

Hale, G ;

Waldmann, H ;

Compston, DA .

JOURNAL OF NEUROLOGY, 2006, 253 (01) :98-108

[6]

Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670

[7] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial [J].

Coles, Alasdair J. ;

Twyman, Cary L. ;

Arnold, Douglas L. ;

Cohen, Jeffrey A. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Miller, Tamara ;

Fisher, Elizabeth ;

Sandbrink, Rupert ;

Lake, Stephen L. ;

Margolin, David H. ;

Oyuela, Pedro ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1829-1839

[8]

Costelloe L, 2012, EXPERT REV NEUROTHER, V12, P335, DOI [10.1586/ERN.12.5, 10.1586/ern.12.5]

[9] Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis [J].

Cox, AL ;

Thompson, SAJ ;

Jones, JL ;

Robertson, VH ;

Haley, G ;

Waldmann, H ;

Compston, DAS ;

Coles, AJ .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (11) :3332-3342

[10] Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis [J].

Hirst, C. L. ;

Pace, A. ;

Pickersgill, T. P. ;

Jones, R. ;

McLean, B. N. ;

Zajicek, J. P. ;

Scolding, N. J. ;

Robertson, N. P. .

JOURNAL OF NEUROLOGY, 2008, 255 (02) :231-238

← 1 2 →